Novo Nordisk has faced challenges in impressing Wall Street with its recent financial results and clinical progress. Despite this, the company has the potential to innovate in its core specialty and beyond, making its stock an attractive investment opportunity. With a 52% drop in share price over the past year, Novo Nordisk’s stock could potentially double in value over the next six years. The company’s focus on diabetes treatments, strong pipeline in weight management, and strategic acquisitions position it well for future growth. While the market remains unimpressed, Novo Nordisk’s stock is currently undervalued, presenting a buying opportunity for investors.

Read more at Nasdaq: A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money